Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001213900-23-065912
Filing Date
2023-08-11
Accepted
2023-08-11 09:00:41
Documents
8

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea182795-s3_actiniumpharma.htm S-3 313444
2 OPINION OF HAYNES AND BOONE LLP ea182795ex5-1_actinium.htm EX-5.1 26840
3 CONSENT OF MARCUM LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ea182795ex23-1_actinium.htm EX-23.1 2172
4 FILING FEE TABLE ea182795ex-fee_actinium.htm EX-FILING FEES 102018
5 GRAPHIC image_001.jpg GRAPHIC 12681
6 GRAPHIC image_002.jpg GRAPHIC 12681
7 GRAPHIC image_003.jpg GRAPHIC 27547
8 GRAPHIC image_004.jpg GRAPHIC 27547
  Complete submission text file 0001213900-23-065912.txt   556886
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-273911 | Film No.: 231161748
SIC: 2834 Pharmaceutical Preparations